AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33395602 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary disgust appraisal reappraisal script
Number of subjects: 52
Study 33395602 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary disgust appraisal reappraisal script
Number of subjects: 52
Study 33395602 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no reappraisal script)
Number of subjects: 52
Study 36149910 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 19
Study 36149910 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 19
Study 34028359 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care mode exercise prescriptions
Number of subjects: 177
Study 34028359 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific fitness mode exercise prescriptions
Number of subjects: 177
Study 35794786 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter in addition to standard information (intervention group)
Number of subjects: 136
Study 35794786 — intervention group
Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 136
Study 35794786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 136
Study 33677411 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone taper
Number of subjects: 25
Study 33677411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 32990919 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN–NA SOT
Number of subjects: 132
Study 32990919 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN monotherapy
Number of subjects: 132
Study 35318238 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) during exercise
Number of subjects: 18
Study 34052096 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG-raising therapies
Number of subjects: 0
Study 35766658 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention with daily multidisciplinary rounds by remote intensivists
Number of subjects: 30
Study 35766658 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 35766658 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 30
Study 33413462 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA + W (34.7 g protein, 24 g EAA)
Number of subjects: 10
Study 33413462 — intervention group
Group type: EXPERIMENTAL
Intervention: MEAL (34.7 g protein, 11.4 g EAA)
Number of subjects: 10
Study 35665994 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session psychological intervention for chronic pain
Number of subjects: 60
Study 35665994 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 32039934 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone
Number of subjects: 1241
Study 32039934 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1241
Study 32039934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain improvement at week 4
Number of subjects: 1241
Study 34860207 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness program
Number of subjects: 0
Study 34860207 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mindfulness intervention
Number of subjects: 0
Study 34860207 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 0
Study 32609036 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute training workshop on ICD management conversations
Number of subjects: 40
Study 32609036 — intervention group
Group type: EXPERIMENTAL
Intervention: Preworkshop self-assessment
Number of subjects: 40
Study 32609036 — intervention group
Group type: EXPERIMENTAL
Intervention: Postworkshop self-assessment
Number of subjects: 40
Study 35987472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Tocilizumab + Standard of Care (SOC)
Number of subjects: 12
Study 35987472 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 12
Study 33177818 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Lung Denervation (TLD)
Number of subjects: 82
Study 33177818 — intervention group
Group type: COMPARATOR
Intervention: Sham bronchoscopy
Number of subjects: 82
Study 36366206 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Stretching (AS) training
Number of subjects: 20
Study 36366206 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study 32426884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 65
Study 32426884 — intervention group
Group type: COMPARATOR
Intervention: Fumaric Acid Esters (FAE)
Number of subjects: 65
Study 34684499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training 2 times a week (T2)
Number of subjects: 20
Study 34684499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training 4 times a week (T4)
Number of subjects: 20
Study 34684499 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the comparison between T2 and T4)
Number of subjects: 20
Study 33118602 — intervention group
Group type: EXPERIMENTAL
Intervention: THC-rich cannabis oil (24.44 mg/mL of THC and 0.51 mg/mL of CBD), initial dose of one drop (∼1.22 mg of THC and 0.02 mg of CBD) a day, increased according to symptoms
Number of subjects: 17
Study 33118602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 33962656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal microdialysis catheter implanted at the end of surgery
Number of subjects: 200
Study 33962656 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no microdialysis catheter)
Number of subjects: 200
Study 36258217 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM granules combined with PPI step-down therapy
Number of subjects: 174
Study 36258217 — intervention group
Group type: COMPARATOR
Intervention: TCM granules placebo combined with PPI step-down therapy
Number of subjects: 174
Study 34793265 — intervention group
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC (2 mg single dose or titrated doses of 2 + 3 and 2 + 3 + 4 mg at weekly intervals)
Number of subjects: 79
Study 34793265 — intervention group
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC (1, 2, 3, and 4 mg weekly doses)
Number of subjects: 79
Study 34793265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 35033029 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based EHR-integrated prediabetes CDS intervention
Number of subjects: 24
Study 35033029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 32946978 — intervention group
Group type: EXPERIMENTAL
Intervention: First set of coated tablets
Number of subjects: 135
Study 32946978 — intervention group
Group type: EXPERIMENTAL
Intervention: Second set of coated tablets
Number of subjects: 135
Study 35635326 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 763
Study 32556157 — intervention group
Group type: EXPERIMENTAL
Intervention: E + sVIP (entecavir + peg‐IFN alfa‐2a [180 µg every week over 48 weeks] plus sequential HBV vaccination [20 µg of HBsAg on weeks 52, 56, 60, and 76])
Number of subjects: 111
Study 32556157 — intervention group
Group type: EXPERIMENTAL
Intervention: E + cVIP (entecavir + peg‐IFN alfa‐2a + concomitant HBV vaccination [weeks 4, 8, 12, and 28])
Number of subjects: 111
Study 32556157 — intervention group
Group type: COMPARATOR
Intervention: Control (entecavir only)
Number of subjects: 111
Study 32556157 — intervention group
Group type: EXPERIMENTAL
Intervention: E + sVIP
Number of subjects: 111
Study 32556157 — intervention group
Group type: EXPERIMENTAL
Intervention: E + cVIP
Number of subjects: 111
Study 32556157 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 111
Study 32556157 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 111
Study 34470536 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic intervention
Number of subjects: 3386
Study 34470536 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive harms intervention
Number of subjects: 3386
Study 34470536 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 3386
Study 34470536 — intervention group
Group type: EXPERIMENTAL
Intervention: ARISE intervention
Number of subjects: 3386
Study 34470536 — intervention group
Group type: COMPARATOR
Intervention: Unbeneficial test condition (0 lives saved)
Number of subjects: 3386
Study 34470536 — intervention group
Group type: COMPARATOR
Intervention: Beneficial test condition (1 life saved)
Number of subjects: 3386
Study 32583011 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-S (H position)
Number of subjects: 197
Study 32583011 — intervention group
Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 197
Study 32583011 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-S (U position)
Number of subjects: 197
Study 32443306 — intervention group
Group type: EXPERIMENTAL
Intervention: Luofengning granule (LFN‐G)
Number of subjects: 60
Study 32443306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34355279 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 104
Study 34355279 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness
Number of subjects: 104
Study 34355279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 104
Study 32691298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber drain
Number of subjects: 40
Study 32691298 — intervention group
Group type: COMPARATOR
Intervention: Control (no drain)
Number of subjects: 40
Study 32348624 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Biofilm therapy (GBT) with plaque disclosing agent
Number of subjects: 32
Study 32348624 — intervention group
Group type: COMPARATOR
Intervention: Control without plaque disclosing agent
Number of subjects: 32
Study 35551292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin add-on therapy to metformin (1,500 mg per day)
Number of subjects: 767
Study 35551292 — intervention group
Group type: COMPARATOR
Intervention: Placebo add-on therapy to metformin (1,500 mg per day)
Number of subjects: 767
Study 33462708 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 94
Study 33462708 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 94
Study 33462708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 33462708 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh Muscle Density (TMD)
Number of subjects: 94
Study 33462708 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 94
Study 32713349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3R intervention (two facilitated group education sessions, 44 weeks of medication reminders, motivational text messages, and two coaching calls)
Number of subjects: 212
Study 32713349 — intervention group
Group type: EXPERIMENTAL
Intervention: 3R intervention
Number of subjects: 212
Study 32713349 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual clinical care)
Number of subjects: 212
Study 33685920 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMAL programme
Number of subjects: 149
Study 33685920 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study 35306123 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aiTBS
Number of subjects: 45
Study 35306123 — intervention group
Group type: COMPARATOR
Intervention: Sham aiTBS
Number of subjects: 45
Study 33234633 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol adherence
Number of subjects: 192
Study 33234633 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 192
Study 33234633 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 192
Study 35231563 — intervention group
Group type: EXPERIMENTAL
Intervention: No motion cohort (cemented tibial component held without motion)
Number of subjects: 64
Study 35231563 — intervention group
Group type: COMPARATOR
Intervention: Motion cohort (tibial implant taken through gentle range of motion)
Number of subjects: 64
Study 34672950 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 11340
Study 34672950 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11340
Study 32546975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1μg/kg)
Number of subjects: 105
Study 32546975 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg/kg)
Number of subjects: 105
Study 32546975 — intervention group
Group type: COMPARATOR
Intervention: Control (20 mL intravenous saline)
Number of subjects: 105
Study 36443695 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure and Response Prevention (VRERP)
Number of subjects: 36
Study 36443695 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized CBT)
Number of subjects: 36
Study 34702164 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hospital Elder Life Program (HELP)
Number of subjects: 195
Study 34702164 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 195
Study 32833758 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE
Number of subjects: 225
Study 32833758 — intervention group
Group type: COMPARATOR
Intervention: NRP
Number of subjects: 225
Study 32833758 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NRP and HOPE
Number of subjects: 225
Study 34492709 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month cycling aerobic exercise intervention (thrice weekly, moderate-vigorous intensity)
Number of subjects: 0
Study 34492709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise dose
Number of subjects: 0
Study 34349367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided spinal anesthesia
Number of subjects: 60
Study 34349367 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique spinal anesthesia
Number of subjects: 60
Study 34633061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 325
Study 35839558 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 2400 mg daily
Number of subjects: 40
Study 35839558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34199566 — intervention group
Group type: EXPERIMENTAL
Intervention: AMICOPE intervention (multi-domain group-based intervention)
Number of subjects: 0
Study 35583273 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330811 100 mg
Number of subjects: 35
Study 35583273 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330811 300 mg
Number of subjects: 35
Study 35583273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 34937855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride
Number of subjects: 84
Study 34937855 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 84
Study 34937855 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 84
Study 34937855 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Number of subjects: 84
Study 34937855 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 84
Study 32565474 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Management of Childhood Illness (IMCI) algorithm and pulse oximeter
Number of subjects: 1804
Study 32565474 — intervention group
Group type: COMPARATOR
Intervention: IMCI algorithm only
Number of subjects: 1804
Study 35941737 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐IM
Number of subjects: 58
Study 33408274 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose schedule (0, 1, and 6 months) of 20 µg rHBV vaccine IM
Number of subjects: 50
Study 33408274 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-dose schedule (0, 1, 2 and 6 months) of 20 µg rHBV vaccine IM
Number of subjects: 50
Study 33408274 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated 3-dose schedule (0, 1, 2 months) of 20 µg rHBV vaccine IM
Number of subjects: 50
Study 36330694 — intervention group
Group type: EXPERIMENTAL
Intervention: integral physiotherapy
Number of subjects: 60
Study 33676302 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionality writing task
Number of subjects: 240
Study 33676302 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive appearance writing task
Number of subjects: 240
Study 33676302 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management reflection task
Number of subjects: 240
Study 33676302 — intervention group
Group type: COMPARATOR
Intervention: Image exposure (thin-ideal models)
Number of subjects: 240
Study 33676302 — intervention group
Group type: COMPARATOR
Intervention: Active images
Number of subjects: 240
Study 33676302 — intervention group
Group type: COMPARATOR
Intervention: Posed images
Number of subjects: 240
Study 32429738 — intervention group
Group type: EXPERIMENTAL
Intervention: VAR-PE process
Number of subjects: 600
Study 32429738 — intervention group
Group type: COMPARATOR
Intervention: VAR
Number of subjects: 600
Study 35751089 — intervention group
Group type: EXPERIMENTAL
Intervention: Minding the Baby (MTB) intervention
Number of subjects: 250
Study 35751089 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 250
Study 32286685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based intervention with audiovisual presentation on coping strategies
Number of subjects: 1841
Study 32286685 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual donation process)
Number of subjects: 1841
Study 33903923 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cryotherapy (C-group) during the first seven postoperative days
Number of subjects: 102
Study 33903923 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cryotherapy (C-group)
Number of subjects: 102
Study 33903923 — intervention group
Group type: COMPARATOR
Intervention: Regular postoperative care (R-group)
Number of subjects: 102
Study 33903923 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted cryotherapy (C-group) and Regular postoperative care (R-group)
Number of subjects: 102
Study 33714741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4725
Study 33714741 — intervention group
Group type: COMPARATOR
Intervention: High burden of HF signs and symptoms (≥3)
Number of subjects: 4725
Study 33714741 — intervention group
Group type: COMPARATOR
Intervention: Orthopnea
Number of subjects: 4725
Study 33714741 — intervention group
Group type: COMPARATOR
Intervention: Rales
Number of subjects: 4725
Study 35418431 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic ultrasound
Number of subjects: 162
Study 35418431 — intervention group
Group type: COMPARATOR
Intervention: night splint
Number of subjects: 162
Study 35418431 — intervention group
Group type: EXPERIMENTAL
Intervention: therapeutic ultrasound + night splint (combined)
Number of subjects: 162
Study 33307783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy and exercise (group I)
Number of subjects: 120
Study 33307783 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (group II)
Number of subjects: 120
Study 33307783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy only (group III)
Number of subjects: 120
Study 32706708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular View web-based self-management program (12 months access)
Number of subjects: 208
Study 32706708 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 208
Study 34732139 — intervention group
Group type: EXPERIMENTAL
Intervention: LPO-system-lozenge with 0.083% H2O2 (B)
Number of subjects: 0
Study 34732139 — intervention group
Group type: EXPERIMENTAL
Intervention: LPO-system-lozenge with 0.04% H2O2 (C)
Number of subjects: 0
Study 34732139 — intervention group
Group type: COMPARATOR
Intervention: Listerine rinse (A)
Number of subjects: 0
Study 34732139 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge (D)
Number of subjects: 0
Study 33168073 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantel–Haenszel method
Number of subjects: 0
Study 33168073 — intervention group
Group type: EXPERIMENTAL
Intervention: Random intercept model
Number of subjects: 0
Study 33168073 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equation (GEE)
Number of subjects: 0
Study 33168073 — intervention group
Group type: EXPERIMENTAL
Intervention: GEE with small sample correction
Number of subjects: 0
Study 33168073 — intervention group
Group type: EXPERIMENTAL
Intervention: No center adjustment
Number of subjects: 0
Study 35817125 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 30 s star jumping
Number of subjects: 12
Study 35817125 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 30 s star jumping
Number of subjects: 12
Study 35817125 — intervention group
Group type: COMPARATOR
Intervention: Resting control (CONT)
Number of subjects: 12
Study 34184475 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospecta
Number of subjects: 275
Study 34184475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 35581126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist collaborative prescribing model
Number of subjects: 0
Study 35581126 — intervention group
Group type: COMPARATOR
Intervention: Usual medical prescribing model
Number of subjects: 0
Study 33963847 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-scoring model developed using multivariate logistic regression analysis.
Number of subjects: 45558
Study 32184025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention with immunonutrition
Number of subjects: 0
Study 32184025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 0
Study 35447039 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular and oscillating breast massage device used for 10 to 15 minutes, three times a day, for 3 days
Number of subjects: 120
Study 35447039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 120